Sanofi Acquires Vigil Neuroscience for $470M, Expands Alzheimer’s Pipeline

Published on Spencer Knight via LinkedIn

Sanofi has agreed to acquire Vigil Neuroscience in a $470 million deal, reinforcing its investment in Alzheimer’s disease and neuroinflammation. The acquisition includes VG-3927, a TREM2 agonist designed to restore microglial function and slow Alzheimer’s progression in its early stages.

The deal includes $8 per share upfront plus a $2 CVR tied to drug milestones. It builds on Sanofi’s earlier $40M equity stake and gives them exclusive rights to Vigil’s neuroinflammation pipeline, while excluding their prior VGL101 program, now returned to Amgen.

Spencer Knight notes this gives Sanofi a new foothold in Alzheimer’s innovation, placing them in competition with Denali, Biogen, and Eisai.

Read the full post on LinkedIn:

👉 Spencer Knight: Sanofi Makes $470M Alzheimer’s Acquisition

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.